Company developing transformative gene-based medicines for serious human diseases
We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases
Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic.
Visit website: http://www.crisprtx.com/
CRISPR Therapeutics News
CRISPR's gene editing therapy finds cure for blood cancer
STAT - 05-Dec-2020
Early data from Vertex & CRISPR showed promising results to cure blood disordersRead more...
Company introduces 'gene writing', to surpass CRISPR's limitations
Wired - 07-Jul-2020
New class of gene editors set to remove hurdles of traditional gene therapyRead more...
CRISPR gene editing to cure beta thalassaemia and sickle cell disease
New Scientist - 12-Jun-2020
Didn't change the inherited faulty gene, but gene to switch on fetal haemoglobin productionRead more...
First attempt to use CRISPR tool to treat a genetic disorder
NPR - 29-Jul-2019
Cells are being taken from patients' bone marrow and genetically modified with CRISPRRead more...
Gene Therapies to Greatly Reduce the Incidence of Cardiovascular Disease
Fight Aging! - 09-Mar-2018
Gene therapy could disable genes that sustain levels of lipids in the bloodstream. Number of cre...Read more...